Exemestane
- Generic Name
- Exemestane
- Brand Names
- Aromasin
- Drug Type
- Small Molecule
- Chemical Formula
- C20H24O2
- CAS Number
- 107868-30-4
- Unique Ingredient Identifier
- NY22HMQ4BX
- Background
Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition.
- Indication
For the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.
- Associated Conditions
- Stage I Breast Cancer, Refractory, advanced Breast cancer
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2021-05-28
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Tolmar Inc.
- Target Recruit Count
- 250
- Registration Number
- NCT04906395
- Locations
- 🇺🇸
Texas Oncology- Deke Slayton Cancer Center, Webster, Texas, United States
🇧🇷Hospital Araujo Jorge, Goiania, Goias, Brazil
🇺🇸Marin Cancer Care, Inc, Greenbrae, California, United States
Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- Veru Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT04869943
- Locations
- 🇺🇸
Banner Health/ Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Texas Oncology Sammons Cancer Center, Dallas, Texas, United States
🇺🇸University of Miami- Sylvester Comprehensive Cancer Center, Miami, Florida, United States
Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.
- Conditions
- Breast Cancer Stage IV
- Interventions
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2021-04-21
- Lead Sponsor
- Blokhin's Russian Cancer Research Center
- Target Recruit Count
- 1000
- Registration Number
- NCT04852081
- Locations
- 🇷🇺
N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russian Federation
Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2020-12-14
- Lead Sponsor
- First Hospital of China Medical University
- Target Recruit Count
- 1354
- Registration Number
- NCT04666805
- Locations
- 🇨🇳
The First Hospital of China Medical University, Shenyang, Liaoning, China
Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer Patients
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- Istituto Oncologico Veneto IRCCS
- Target Recruit Count
- 43
- Registration Number
- NCT04659551
- Locations
- 🇮🇹
Arcispedale S. Anna, Cona, FE, Italy
🇮🇹Azienda Ospedaliera Universitaria di Parma, Parma, PR, Italy
🇮🇹Arcispedale S. Maria Nuova, Reggio Emilia, RE, Italy
A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2020-10-01
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 51
- Registration Number
- NCT04572295
- Locations
- 🇯🇵
Eisai Trial Site 10, Kitaadachi-gun, Saitama, Japan
🇯🇵Eisai Trial Site 2, Shinagawa-ku, Tokyo, Japan
🇯🇵Eisai Trial Site 6, Kashiwa, Chiba, Japan
Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
- Target Recruit Count
- 30
- Registration Number
- NCT04465097
- Locations
- 🇨🇳
The first affiliated hospital of Sun Yat-Sen university, Guangzhou, Guangdong, China
Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer
- First Posted Date
- 2020-07-08
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Ente Ospedaliero Ospedali Galliera
- Target Recruit Count
- 23
- Registration Number
- NCT04460807
- Locations
- 🇮🇹
ASST degli Spedali Civili di Brescia, Brescia, BS, Italy
🇮🇹Azienda Ospedaliera per l'emergenza Cannizzaro, Catania, CT, Italy
🇮🇹UOS Oncologia Ginecologica, Ospedale S. Gerardo, Monza, MB, Italy
Relationship Between Body Composition, Food Consumption, and Micro and Macronutrients With Gene Expression in Breast Cancer
- Conditions
- Endocrine TherapyVitamin D DeficiencyBreast CancerEndocrine Therapy Adverse ReactionNutrition DisordersObesity
- Interventions
- First Posted Date
- 2020-05-15
- Last Posted Date
- 2020-05-15
- Lead Sponsor
- Instituto Jalisciense de Cancerologia
- Target Recruit Count
- 300
- Registration Number
- NCT04389424
- Locations
- 🇲🇽
Instituto Jalisciense de Cancerologia, Guadalajara, Jalisco, Mexico
Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2020-03-09
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- MedSIR
- Target Recruit Count
- 69
- Registration Number
- NCT04300790
- Locations
- 🇪🇸
Hospital General Universitario de Alicante, Alicante, Spain
🇪🇸Hospital Universitario de Leon, León, Spain
🇪🇸Hospital Beata María Ana, Madrid, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.